Activity Details

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

Clinicians who diagnose and manage patients with cytomegalovirus (CMV) infection and disease.

Learning Objectives

After completing this activity, the clinician should be able to:

• Summarize existing and emerging therapies for the prevention and treatment of cytomegalovirus (CMV) disease in solid organ transplant (SOT) patients
• Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities
• Identify risk factors and emerging therapies for resistant CMV disease

Activity Description

This activity will bring you face-to-face with Drs. Kotton, Silveira, and Pereira as they discuss the many facets of cytomegalovirus (CMV) infection in solid organ transplant (SOT) patients. They will share clinical insights on emerging treatments for resistant and refractory CMV disease, as well as tips for avoiding and managing the challenging side effects of current antiviral therapies. You will be captivated as you watch a first-hand account of life-altering CMV when a lung transplant patient shares his journey with resistant CMV, how CMV treatments and side effects impacted his life, and his advice for healthcare professionals.

Faculty

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Marcus Pereira, MD, MPH, FAST
Assistant Professor of Medicine
Medical Director, Transplant Infectious Disease Program
Columbia University Medical Center
New York, NY

Fernanda P. Silveira, MD, MS, FIDSA, FAST
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Hookipa, Merck, Shire/Takeda (Consultant).

Marcus Pereira, MD, MPH, FAST, has no relevant financial relationships with ineligible companies to disclose.

Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Ansun, Merck, Slieagen, Takeda (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationships with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.75 contact hour(s) (0.75 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-002-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete activity evaluation and attest to credit
• Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
• Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For questions regarding this activity, please contact Linda Hopkins at lhopkins@rmei.com

Activity Details

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

Clinicians who diagnose and manage patients with cytomegalovirus (CMV) infection and disease.

Learning Objectives

After completing this activity, the clinician should be able to:

• Summarize existing and emerging therapies for the prevention and treatment of cytomegalovirus (CMV) disease in solid organ transplant (SOT) patients
• Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities
• Identify risk factors and emerging therapies for resistant CMV disease

Activity Description

This activity will bring you face-to-face with Drs. Kotton, Silveira, and Pereira as they discuss the many facets of cytomegalovirus (CMV) infection in solid organ transplant (SOT) patients. They will share clinical insights on emerging treatments for resistant and refractory CMV disease, as well as tips for avoiding and managing the challenging side effects of current antiviral therapies. You will be captivated as you watch a first-hand account of life-altering CMV when a lung transplant patient shares his journey with resistant CMV, how CMV treatments and side effects impacted his life, and his advice for healthcare professionals.

Faculty

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Marcus Pereira, MD, MPH, FAST
Assistant Professor of Medicine
Medical Director, Transplant Infectious Disease Program
Columbia University Medical Center
New York, NY

Fernanda P. Silveira, MD, MS, FIDSA, FAST
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Hookipa, Merck, Shire/Takeda (Consultant).

Marcus Pereira, MD, MPH, FAST, has no relevant financial relationships with ineligible companies to disclose.

Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Ansun, Merck, Slieagen, Takeda (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationships with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.75 contact hour(s) (0.75 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-002-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete activity evaluation and attest to credit
• Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
• Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For questions regarding this activity, please contact Linda Hopkins at lhopkins@rmei.com

Activity Details

Accredited By

This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.

Target Audience

The target audiences are rheumatologists and nurse practitioner (NP)/physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with psoriatic arthritis (PsA) can benefit from participation in this education.

Learning Objectives

As a result of participation in this initiative, participants will increase their ability to:

1. Use augmented reality (AR) apps for providers and patients on mechanisms of action (MOAs) of therapies for treatment of PsA.
2. Discuss effectiveness and safety of conventional, biologic, and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
3. Apply evolving recommendations and clinical practice guidelines related to COVID-19 infection and vaccination to providing care to patients with PsA.
4. Inform patients with PsA about the impact of their disease and the benefits and risks of medications in the context of COVID-19 infection and vaccination when making shared decisions about treatment plan and treatment modifications.

Activity Description

COVID-19 has impacted PsA patient care in many ways, particularly for patients with multiple comorbidities. This interactive activity reviews clinical practice guidelines addressing COVID-19 infection and vaccination that are relevant to patients with PsA, highlights effectiveness and safety of therapies for PsA, and offers a self-directed experience of building and solving patient cases to learn from making decisions and receiving immediate feedback. This activity also incorporates the patient perspective, a skill-oriented presentation on engaging patients in shared decision making, decision aids, and a demonstration of an augmented reality (AR) app on PsA for healthcare providers and patients.

Please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device to gain the most benefit from participation in this activity. You may use this QR code or search for it in Google Play or the App Store.

For the best experience, use a laptop, desktop, or tablet with the Google Chrome browser.

Agenda

1. Providing Psoriatic Arthritis Care During the COVID-19 Pandemic
2. Using Shared Decision Making to Engage Patients With Psoriatic Arthritis to Clarify Treatment Goals in the Context of COVID-19
3. Demonstration of Augmented Reality App for Providers and Patients
4. Personalized Patient Cases

Faculty

Atul A. Deodhar, MD, MRCP, FACR, FACP
Professor of Medicine,
Medical Director of Rheumatology Clinics,
Division of Arthritis & Rheumatic Diseases
Oregon Health & Science University
Portland, Oregon

Richard Martin, MD, MA
Professor of Medicine and Rheumatology,
Michigan State University College of Human Medicine
Grand Rapids, Michigan

David Kramer
Patient Presenter

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies.* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

*The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies—unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

The following individuals have indicated that they have not had, in the past 24 months, a relevant financial relationship(s) with ineligible companies to disclose:

• Planners (Forefront Collaborative): Leah Johnson and Marianna Shershneva, MD, PhD
• Planners (Faculty): Linda Grinnell-Merrick, MS, NP-BC
• Patient Presenter: David Kramer
• Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN, and Bernadette Marie Makar, MSN, APRN, BC, NP-C

The following individuals have disclosed that they have had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

Faculty Presenter: Atul A. Deodhar, MD, MRCP, FACR, FACP

• Consultant: Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB
• Speaker: Eli Lilly, Janssen, Novartis, Pfizer
• Independent contractor (including contracted research): AbbVie, Amgen, Celgene, Eli Lilly, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB

Faculty Presenter: Richard Martin, MD, MA

• Contracted Research/Current Clinical Trials: AbbVie, Eli Lilly

Faculty Planner: Alvin F. Wells, MD, PhD, FACR

• Speakers Bureau: AbbVie, Amgen, BMS, Eli Lilly, Novartis, Pfizer, Sanofi

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Physicians
Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

This activity is approved for 1.0 contact hour (which includes 0.25 hours of pharmacology).

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include references to unlabeled or unapproved uses of drugs.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

Activity Details

Accredited By

This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.

Target Audience

The target audiences are rheumatologists and nurse practitioner (NP)/physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with psoriatic arthritis (PsA) can benefit from participation in this education.

Learning Objectives

As a result of participation in this initiative, participants will increase their ability to:

1. Use augmented reality (AR) apps for providers and patients on mechanisms of action (MOAs) of therapies for treatment of PsA.
2. Discuss effectiveness and safety of conventional, biologic, and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
3. Apply evolving recommendations and clinical practice guidelines related to COVID-19 infection and vaccination to providing care to patients with PsA.
4. Inform patients with PsA about the impact of their disease and the benefits and risks of medications in the context of COVID-19 infection and vaccination when making shared decisions about treatment plan and treatment modifications.

Activity Description

COVID-19 has impacted PsA patient care in many ways, particularly for patients with multiple comorbidities. This interactive activity reviews clinical practice guidelines addressing COVID-19 infection and vaccination that are relevant to patients with PsA, highlights effectiveness and safety of therapies for PsA, and offers a self-directed experience of building and solving patient cases to learn from making decisions and receiving immediate feedback. This activity also incorporates the patient perspective, a skill-oriented presentation on engaging patients in shared decision making, decision aids, and a demonstration of an augmented reality (AR) app on PsA for healthcare providers and patients.

Please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device to gain the most benefit from participation in this activity. You may use this QR code or search for it in Google Play or the App Store.

For the best experience, use a laptop, desktop, or tablet with the Google Chrome browser.

Agenda

1. Providing Psoriatic Arthritis Care During the COVID-19 Pandemic
2. Using Shared Decision Making to Engage Patients With Psoriatic Arthritis to Clarify Treatment Goals in the Context of COVID-19
3. Demonstration of Augmented Reality App for Providers and Patients
4. Personalized Patient Cases

Faculty

Atul A. Deodhar, MD, MRCP, FACR, FACP
Professor of Medicine,
Medical Director of Rheumatology Clinics,
Division of Arthritis & Rheumatic Diseases
Oregon Health & Science University
Portland, Oregon

Richard Martin, MD, MA
Professor of Medicine and Rheumatology,
Michigan State University College of Human Medicine
Grand Rapids, Michigan

David Kramer
Patient Presenter

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies.* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

*The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies—unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

The following individuals have indicated that they have not had, in the past 24 months, a relevant financial relationship(s) with ineligible companies to disclose:

• Planners (Forefront Collaborative): Leah Johnson and Marianna Shershneva, MD, PhD
• Planners (Faculty): Linda Grinnell-Merrick, MS, NP-BC
• Patient Presenter: David Kramer
• Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN, and Bernadette Marie Makar, MSN, APRN, BC, NP-C

The following individuals have disclosed that they have had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

Faculty Presenter: Atul A. Deodhar, MD, MRCP, FACR, FACP

• Consultant: Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB
• Speaker: Eli Lilly, Janssen, Novartis, Pfizer
• Independent contractor (including contracted research): AbbVie, Amgen, Celgene, Eli Lilly, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB

Faculty Presenter: Richard Martin, MD, MA

• Contracted Research/Current Clinical Trials: AbbVie, Eli Lilly

Faculty Planner: Alvin F. Wells, MD, PhD, FACR

• Speakers Bureau: AbbVie, Amgen, BMS, Eli Lilly, Novartis, Pfizer, Sanofi

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Physicians
Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

This activity is approved for 1.0 contact hour (which includes 0.25 hours of pharmacology).

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include references to unlabeled or unapproved uses of drugs.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

Activity Details

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

• Summarize the current guidelines and recommendations for the treatment of PAH
• Develop individualized treatment regimens based on the multidisciplinary approach to care for PAH that takes into account treatment goals, short-and-long-term assessment, and comorbidities in order to improve patient outcomes

Faculty

Sonja Bartolome, MD, FCCP
Professor, Pulmonary and Critical Care Medicine
Associate Chief Quality Officer
UT Southwestern Medical Center
Dallas, TX

Dr. Bartolome discloses the following:
Consulting Fees: Janssen

Ronald J. Oudiz, MD, FACP, FACC, FCCP
Investigator, The Lundquist Institute
Professor of Medicine, David Geffen School of Medicine at UCLA
Director, Liu Center for Pulmonary Hypertension, The Lundquist Institute
Torrance, CA

Dr. Oudiz discloses the following:
Consulting Fees: Gilead, Gossamer, Insmed, JnJ, Liquidia, Respira, United Therapeutics, V-Wave
Fees for Non-CME Services Received Directly from a Commercial Interest: JnJ, United Therapeutics, V-Wave
Contracted Research: AADi, Gossamer, Insmed, JnJ, Liquidia, United Therapeutics, V-Wave

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2782-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

Activity Details

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

• Summarize the current guidelines and recommendations for the treatment of PAH
• Develop individualized treatment regimens based on the multidisciplinary approach to care for PAH that takes into account treatment goals, short-and-long-term assessment, and comorbidities in order to improve patient outcomes

Faculty

Sonja Bartolome, MD, FCCP
Professor, Pulmonary and Critical Care Medicine
Associate Chief Quality Officer
UT Southwestern Medical Center
Dallas, TX

Dr. Bartolome discloses the following:
Consulting Fees: Janssen

Ronald J. Oudiz, MD, FACP, FACC, FCCP
Investigator, The Lundquist Institute
Professor of Medicine, David Geffen School of Medicine at UCLA
Director, Liu Center for Pulmonary Hypertension, The Lundquist Institute
Torrance, CA

Dr. Oudiz discloses the following:
Consulting Fees: Gilead, Gossamer, Insmed, JnJ, Liquidia, Respira, United Therapeutics, V-Wave
Fees for Non-CME Services Received Directly from a Commercial Interest: JnJ, United Therapeutics, V-Wave
Contracted Research: AADi, Gossamer, Insmed, JnJ, Liquidia, United Therapeutics, V-Wave

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2782-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

Activity Details

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

• Incorporate risk stratification methods for selecting and modifying therapy in patients with PAH
• Evaluate the efficacy and safety of current and emerging therapeutic options for PAH
• Review the evidence for initiating combination therapy in patients with PAH

Faculty

Nazzareno Galiè, MD
Professore Ordinario di Cardiologia
Direttore U.O.C. di Cardiologia, IRCCS-Policlinico di S.Orsola, Bologna
Direttore della Scuola di Specializzazione in
Malattie dell’Apparato Cardiovascolare
Bologna, Italy

Dr. Galiè discloses the following:
Consulting Fees: Janssen, Actelion, Ferrer, Pfizer
Contracted Research: Janssen

Gerald Simonneau, MD
French Reference Center for PH
Emeritus Professor University Paris-Saclay
Paris, France

Dr. Simonneau discloses the following:
Consulting Fees: Actelion, Bayer, MSA
Fees for Non-CME Services Received Directly from a Commercial Interest: Actelion, Bayer, MSA

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2780-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

Activity Details

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

• Incorporate risk stratification methods for selecting and modifying therapy in patients with PAH
• Evaluate the efficacy and safety of current and emerging therapeutic options for PAH
• Review the evidence for initiating combination therapy in patients with PAH

Faculty

Nazzareno Galiè, MD
Professore Ordinario di Cardiologia
Direttore U.O.C. di Cardiologia, IRCCS-Policlinico di S.Orsola, Bologna
Direttore della Scuola di Specializzazione in
Malattie dell’Apparato Cardiovascolare
Bologna, Italy

Dr. Galiè discloses the following:
Consulting Fees: Janssen, Actelion, Ferrer, Pfizer
Contracted Research: Janssen

Gerald Simonneau, MD
French Reference Center for PH
Emeritus Professor University Paris-Saclay
Paris, France

Dr. Simonneau discloses the following:
Consulting Fees: Actelion, Bayer, MSA
Fees for Non-CME Services Received Directly from a Commercial Interest: Actelion, Bayer, MSA

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2780-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.